News
RDHL
5.23
-2.48%
-0.13
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 2d ago
Weekly Report: what happened at RDHL last week (0203-0207)?
Weekly Report · 5d ago
RedHill Biopharma Launches Phase 2 Trial For Advanced Prostate Cancer Treatment
NASDAQ · 02/04 22:26
RedHill Biopharma Initiates Phase 2 Study on Prostate Cancer Treatment
TipRanks · 02/04 12:29
RedHill Biopharma begins Phase 2 study of prostate cancer combination
TipRanks · 02/04 12:25
RedHill Biopharma Engages in Strategic Market Offering to Boost Financial Flexibility
TipRanks · 02/03 21:49
Redhill Biopharma May Offer, Sell ADS Of Up To $3.5M From Time To Time; Entered Into At Market Offering Agreement Relating To Offer From Time To Time Of ADSs Offered By Prospectus Supplement
Benzinga · 02/03 21:29
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 02/03 21:05
Weekly Report: what happened at RDHL last week (0127-0131)?
Weekly Report · 02/03 10:28
Weekly Report: what happened at RDHL last week (0120-0124)?
Weekly Report · 01/27 10:30
RedHill Biopharma Expands Medicare Coverage and Simplifies Talicia Dosing
TipRanks · 01/21 12:28
RedHill Biopharma’s Talicia now covered by Humana’s Part D Plan
TipRanks · 01/21 12:10
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 01/21 12:07
Weekly Report: what happened at RDHL last week (0113-0117)?
Weekly Report · 01/20 10:24
Weekly Report: what happened at RDHL last week (0106-0110)?
Weekly Report · 01/13 10:25
Weekly Report: what happened at RDHL last week (1230-0103)?
Weekly Report · 01/06 10:30
Weekly Report: what happened at RDHL last week (1223-1227)?
Weekly Report · 12/30/2024 10:26
Weekly Report: what happened at RDHL last week (1216-1220)?
Weekly Report · 12/23/2024 10:30
Weekly Report: what happened at RDHL last week (1209-1213)?
Weekly Report · 12/16/2024 10:31
RedHill Biopharma's Opaganib Demonstrates Protective Activity Against GI-ARS, Paving The Way for Future FDA Approval vVa Animal Rule
Benzinga · 12/10/2024 12:30
More
Webull provides a variety of real-time RDHL stock news. You can receive the latest news about Redhill Biopharm through multiple platforms. This information may help you make smarter investment decisions.
About RDHL
RedHill Biopharma Ltd is an Israel-based specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204, for pulmonary nontuberculous mycobacteria (NTM) disease; opaganib (ABC294640), host-directed, SPHK2 inhibitor targeting multiple indications, RHB-107 (upamostat), an oral, host-directed serine protease inhibitor with potential for pandemic preparedness, is in late-stage development for treatment of non-hospitalized symptomatic COVID-19, and is targeting multiple other cancer and inflammatory gastrointestinal diseases; RHB-104 for Crohn's disease; and RHB-102 for chemotherapy and radiotherapy induced nausea and vomiting.